Sun Pharma Q2 Results FY25–26: Net Profit, Revenue & Highlights

Adani Ports Q2 Results FY25–26: Revenue ₹9,167 Cr Up 30% YoY, Net Profit ₹3,120 Cr Up 29% YoY

Synopsis:


Sun Pharma reported consolidated revenue of ₹1,44,052 crore for Q2 FY26, up 8.6% YoY. Net profit rose 2.6% to ₹31,180 crore amid strong growth in India and Emerging Markets formulations and higher R&D investments.


Source:
 Sun Pharmaceutical Industries Ltd. Board Meeting Outcome & Press Release (BSE Filing) | Published on 05 Nov 2025

Sun Pharmaceutical Industries Limited released its unaudited consolidated financial results for the quarter ended 30 September 2025. The company reported steady year-on-year growth in sales driven by India, Emerging Markets and Rest of World formulations, while profits remained stable despite higher R&D spending.

Sun Pharma Q2 Results FY25–26 Date & Announcement

The Board of Directors approved the unaudited consolidated financial results at its meeting held on 05 November 2025. The meeting commenced at 11:30 A.M. and concluded at 03:40 P.M. No dividend was declared for the quarter.

Sun Pharma Adv Res Co Ltd

Trade

127.5-0.55 (-0.42 %)

Updated - 24 February 2026
129.02day high
DAY HIGH
125.00day low
DAY LOW
473343
VOLUME (BSE)

Sun Pharma Q2 Results FY25–26 – Key Financial Highlights

(All figures in ₹ crore – Consolidated, Unaudited)

Particulars

Q2 FY26

Q1 FY26

Q2 FY25

Revenue from Operations

1,44,052

1,37,861

1,32,642

Other Income

4,699

4,645

3,540

Total Income

1,49,482

1,43,159

1,36,454

EBITDA

45,271

41,624

39,377

Profit Before Tax

41,676

39,908

35,979

Net Profit (PAT)

31,180

22,786

30,402

Total Comprehensive Income

45,404

24,203

34,551

EPS (₹)

13.0

9.5

12.7

R&D Expenses

7,827

9,029

7,929

Sun Pharma Q2 FY25–26 vs Q2 FY24–25 – Comparison

(All figures in ₹ crore – Consolidated)

Metric

Q2 FY26

Q2 FY25

Revenue from Operations

1,44,052

1,32,642

Profit Before Tax

41,676

35,979

Profit After Tax

31,180

30,402

EPS (₹)

13.0

12.7

The company maintained steady revenue growth backed by expansion in India, Emerging Markets and ROW segments along with sustained profitability.

Key Highlights – Sun Pharma Q2 FY25–26

  • India Formulations: ₹47,348 cr, up 11% YoY; 32.9% of total sales.

  • US Formulations: US $496 mn (≈ ₹43,288 cr), down 4.1% YoY; 30.1% of total sales.

  • Emerging Markets: US $325 mn (≈ ₹28,370 cr), up 10.9% YoY.

  • Rest of World Markets: US $234 mn (≈ ₹20,400 cr), up 17.7% YoY.

  • Global Innovative Medicines: US $333 mn (≈ ₹29,000 cr), up 16.4% YoY; 20.2% of total sales.

  • API Sales: ₹4,299 cr, down 19.5% YoY.

  • EBITDA Margin: 31.3%.

  • R&D Investment: ₹7,827 cr (5.4% of sales).

Market Reaction After Sun Pharma Q2 Results FY25–26

The results were announced post-market hours on 05 November 2025. Sun Pharma’s stock closed at ₹1,696.10 on the BSE, marginally up 0.36% ahead of the announcement, reflecting a wait-and-watch approach from investors.

Conclusion – What Sun Pharma Q2 Results Indicate

Sun Pharma’s Q2 FY26 performance reflects broad-based growth driven by domestic and emerging markets with continued momentum in its Innovative Medicines portfolio. While generic pressures weighed on US sales, higher R&D spending underscores the company’s focus on long-term innovation and product diversification.

Disclaimer:This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.

 

Frequently Asked Questions

No result found

search icon
Published Date : 06 Nov 2025

Disclaimer :

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.8 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,300+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|